Forbion Raises $2.6B for Pair of Venture Funds

Forbion has raised $2.6B for a pair of venture funds, according to Biopharma Dive. The publication described the financing as the biotech investor’s largest fundraise to date.

Biopharma Dive characterized Forbion as a prominent biotech investor and reported that the capital was raised for two venture funds. The fundraise is a notable financing event within the biotech investment landscape.

Fundraise details

The $2.6B raise is Forbion’s largest to date, Biopharma Dive reported. The funding is designated for a pair of venture funds.

For medical and pharmaceutical sales professionals following the biotech business environment, the announcement centers on a major venture-fund financing by a named investor. Biopharma Dive’s report identifies both the scale of the raise and the two-fund structure.

The publication’s account does not identify portfolio companies, product areas, individual investments, or commercial programs connected to the funds. The reported event is Forbion’s raise for the venture funds.

European biotech context

Biopharma Dive said the fundraise provides a lift for the European biotech industry. The publication reported that the industry has fallen further behind its counterparts in the U.S. and China.

That context places Forbion’s financing within the broader European biotech sector described by Biopharma Dive. The publication connected the firm’s largest fundraise to date with a European industry it said has lagged behind counterparts in the U.S. and China.

Key points reported by Biopharma Dive

• Forbion raised $2.6B.
• The capital is for a pair of venture funds.
• The raise is Forbion’s largest to date.
• Biopharma Dive described Forbion as a prominent biotech investor.
• The publication said the financing provides a lift for European biotech.

The announcement adds a funding milestone to the biotech investment news cycle, with Biopharma Dive reporting the amount, the pair of venture funds, and the European biotech context surrounding the raise.